Acute Gout Flare Market Poised for Significant Growth by 2034, DelveInsight Report | Featuring Leading Companies Including Dyve Biosciences, Olatec Therapeutics, and Novartis Pharmaceuticals

The report analyzes the existing treatment practices and unmet medical requirements in Acute Gout Flare. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.
Emerging therapies for acute gout flare, including IDYV700, OLT1177 (Dapansutrile), XRx-026, and others, are anticipated to drive growth in the acute gout flare market in the coming years.

DelveInsight has launched a new report on "Acute Gout Flare - Market Insights, Epidemiology, and Market Forecast-2034 [https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" that delivers an in-depth understanding of the acute gout flare, historical and forecasted epidemiology as well as the Acute Gout Flare market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Acute Gout Flare Market Report:

*
In June 2024, the FDA approved a supplemental New Drug Application (sNDA) for GLOPERBA, the first and only liquid oral formulation of colchicine. Gloperba is indicated for preventing painful gout flares in adults and provides precision dosing, making it particularly useful for patients with chronic kidney disease.

*
A novel investigational combination therapy for chronic refractory gout (CRG) received Fast Track designation from the FDA in March 2024, with a rolling Biologics License Application (BLA) currently submitted. Analysis indicates that the annual incidence of gout in the UK is 2.68 cases per 1,000 individuals. In the United States, rising incidence has brought gout to over 8 million affected individuals.

*
Men are more prone to gout than women due to higher uric acid levels, with prevalence in Western countries estimated at 3-6% for men and 1-2% for women. In some regions, prevalence may reach up to 10%.

*
Key companies developing treatments for acute gout flares include Dyve Biosciences, XORTX Therapeutics, Shanton Pharma, InventisBio, Olatec Therapeutics, Novartis Pharmaceuticals, and others. Promising pipeline therapies in various stages of development include IDYV700, XRx-026, OLT1177, ILARIS, and additional candidates.

Key benefits of the Acute Gout Flare market report:

*
Acute gout flare market report covers a descriptive overview and comprehensive insight of the acute gout flare Epidemiology and acute gout flare market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The acute gout flare market report provides insights into the current and emerging therapies.

*
The acute gout flare market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The acute gout flare market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the acute gout flare market.

Got queries? Click here to know more about the acute gout flare market landscape [https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Acute Gout Flare Overview

Gout is an inflammatory form of arthritis caused by the accumulation of monosodium urate (MSU) crystals in the joints, often arising from hyperuricemia. The disease progresses through four stages: asymptomatic hyperuricemia, acute gout attacks, intercritical periods (between flares), and, if left untreated, chronic tophaceous gout. Early diagnosis and proper treatment can effectively manage the condition.

Gout attacks can severely affect a patient's quality of life, causing intense joint pain, swelling, restricted mobility, and overall discomfort. Epidemiological data show that gout is increasingly prevalent, now impacting over 3% of the adult population in the United States.

Several risk factors contribute to gout development, including genetics, age, gender, and diet. Elevated blood uric acid levels, defined as 6.8 mg/dL (405 mol/L) or higher, are the primary risk factor. Men are more commonly affected than women, and the condition is particularly prevalent in individuals over 60. Genetic predisposition also plays a key role, while diets rich in red meat, seafood, sugary drinks, fructose, and alcohol can further raise the risk of hyperuricemia and subsequent gout.

Acute Gout Flare Market Outlook

Treatment of acute gout attacks usually starts with first-line therapies such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), COX-2 inhibitors, corticosteroids, colchicine, or targeted steroid injections. The main objective is rapid pain relief and swift resolution of symptoms. However, acute flares can recur, with shorter intervals between episodes, potentially progressing to chronic gout. Chronic cases may involve ongoing joint inflammation (synovitis), bone erosion, cartilage damage, and formation of tophi.

For patients experiencing frequent flares who cannot tolerate NSAIDs, colchicine, or corticosteroids, the European League Against Rheumatism (EULAR) recommends IL-1 inhibitors. Canakinumab, a long-acting monoclonal antibody targeting IL-1 beta, has been approved by the European Medicines Agency following two randomized controlled trials versus intramuscular triamcinolone acetonide. Anakinra, an IL-1 receptor antagonist, is also used off-label in similar scenarios. Additionally, urate-lowering therapies (ULTs) are prescribed to maintain normal serum uric acid levels.

With ongoing research into various IL-1 blockers, the acute gout flare treatment landscape is poised for significant evolution. These therapies have shown strong safety and tolerability profiles, offering promise for improved patient management.

Explore how the acute gout flare market [https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] is rising in the upcoming years

Acute Gout Flare Therapies and Key Companies

*
OLT1177 (Dapansutrile): Olatec Therapeutics

*
DYV700: Dyve Biosciences

*
XRx-026: XORTX Therapeutics

To know more about the therapies that are driving the acute gout flare treatment market, visit: https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Scope of the Acute Gout Flare Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Acute Gout Flare Companies:Dyve Biosciences, XORTX Therapeutics, Shanton Pharma, InventisBio, Olatec Therapeutics, Novartis Pharmaceuticals and others

*
Key Acute Gout Flare Therapies: IDYV700, OLT1177 (Dapansutrile), XRx-026, and others

*
Acute Gout Flare Therapeutic Assessment: Acute gout flare current marketed and Acute Gout Flare emerging therapies

*
Acute Gout Flare Market Dynamics: Acute gout flare market drivers and acute gout flare market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Acute Gout Flare Unmet Needs, KOL's views, Analyst's views, Acute Gout Flare Market Access and Reimbursement

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Acute Gout Flare Patient Share (%) Overview at a Glance

5. Acute Gout Flare Market Overview at a Glance

6. Acute Gout Flare Disease Background and Overview

7. Acute Gout Flare Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Gout Flare

9. Acute Gout Flare Current Treatment and Medical Practices

10. Unmet Needs

11. Acute Gout Flare Emerging Therapies

12. Acute Gout Flare Market Outlook

13. Country-Wise Acute Gout Flare Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Acute Gout Flare Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Acute Gout Flare Market Outlook 2034 [https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Acute Gout Flare Pipeline Insights, DelveInsight

"Acute Gout Flare Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the acute gout flare market. A detailed picture of the acute gout flare pipeline landscape is provided, including a disease overview and treatment guidelines for acute gout flare. .

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-gout-flare-market-poised-for-significant-growth-by-2034-delveinsight-report-featuring-leading-companies-including-dyve-biosciences-olatec-therapeutics-and-novartis-pharmaceuticals]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.